Frontier Capital Management Co. LLC Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Frontier Capital Management Co. LLC boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 46.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,002 shares of the specialty pharmaceutical company's stock after acquiring an additional 11,027 shares during the period. Frontier Capital Management Co. LLC owned 0.06% of Jazz Pharmaceuticals worth $4,310,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC raised its position in shares of Jazz Pharmaceuticals by 19.1% in the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock worth $4,369,000 after acquiring an additional 6,289 shares in the last quarter. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 49.8% in the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company's stock worth $76,000 after purchasing an additional 206 shares in the last quarter. Wedmont Private Capital increased its holdings in Jazz Pharmaceuticals by 37.1% in the fourth quarter. Wedmont Private Capital now owns 6,815 shares of the specialty pharmaceutical company's stock worth $827,000 after purchasing an additional 1,843 shares in the last quarter. Cooper Financial Group lifted its stake in Jazz Pharmaceuticals by 3.7% in the fourth quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company's stock valued at $534,000 after buying an additional 156 shares during the period. Finally, Park Avenue Securities LLC boosted its holdings in shares of Jazz Pharmaceuticals by 19.5% during the 4th quarter. Park Avenue Securities LLC now owns 2,521 shares of the specialty pharmaceutical company's stock worth $310,000 after buying an additional 412 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on JAZZ shares. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. StockNews.com cut shares of Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 7th. Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley cut their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their target price for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Stock Down 0.6%

NASDAQ:JAZZ traded down $0.67 on Tuesday, hitting $102.91. The stock had a trading volume of 781,022 shares, compared to its average volume of 837,276. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The firm's fifty day simple moving average is $118.23 and its two-hundred day simple moving average is $122.25. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market cap of $6.34 billion, a P/E ratio of 14.49, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The business had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same period in the previous year, the business posted $2.68 earnings per share. The business's revenue was down .5% compared to the same quarter last year. Analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan acquired 1,621 shares of the stock in a transaction on Monday, May 12th. The shares were acquired at an average price of $103.00 per share, with a total value of $166,963.00. Following the completion of the transaction, the director now owns 101,621 shares in the company, valued at approximately $10,466,963. The trade was a 1.62% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the transaction, the chief executive officer now owns 439,307 shares in the company, valued at approximately $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,236 shares of company stock worth $3,956,190 in the last ninety days. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.